Mazières J, Dansin E
Service de pneumologie, hôpital Larrey, CHU de Toulouse, chemin de Pouvourville, 31059 Toulouse, France.
Rev Pneumol Clin. 2008 Aug;64(4):166-72. doi: 10.1016/j.pneumo.2008.07.004. Epub 2008 Sep 19.
Bevacizumab is an antiangiogenic drug targeting VEGF. Its interest, in combination with chemotherapy, has been demonstrated in two recent trials in metastatic non-small cell lung cancer and its approval is awaited within few weeks. Due its original mechanism of action, bevacizumab has a very specific safety profile and radiological response patterns.
Based upon selected observations reported from patients included in clinical trials and on recent literature, we bring some clue for a better and safer use of bevacizumab.
We report toxicity associated with bevacizumab, especially vascular side-effects and unusual radiological responses.
Bevacizumab use in NSCLC is associated with some unexpected side effects and responses that worth to be known by pulmonologists. Selections criteria should be rigorously followed.
贝伐单抗是一种靶向血管内皮生长因子（VEGF）的抗血管生成药物。近期两项针对转移性非小细胞肺癌的试验已证明其与化疗联合使用的益处，预计在几周内将获得批准。由于其独特的作用机制，贝伐单抗具有非常特殊的安全性和放射学反应模式。
基于临床试验中纳入患者的选定观察结果以及近期文献，我们为更好、更安全地使用贝伐单抗提供了一些线索。
我们报告了与贝伐单抗相关的毒性，尤其是血管副作用和不寻常的放射学反应。
在非小细胞肺癌中使用贝伐单抗会出现一些意想不到的副作用和反应，肺科医生应该了解这些情况。应严格遵循选择标准。
